Eslicarbazepine acetate: An efficacy and safety as an antiepileptic drug in clinical trials and open studies
KeywordsEslicarbazepine acetate, Focal-onset seizures, Monotherapy, Adjunctive therapy
Eslicarbazepine acetate (Zebinix®, ESL), a voltage-gated sodium channel blocker, is a once-daily, orally administered anti-seizure medication available in the EU for use as monotherapy in adults with newly diagnosed partial-onset seizures and as adjunctive therapy in adults, adolescents, and children aged > 6 years with partial-onset seizures. It was approved by the European Medicines Agency and launched onto the European market in 2009.
This study aimed to assess the efficacy and safety of ESL in the treatment of focal-onset seizures. Our study material consisted of publications, which were found in PubMed, Google Scholar, and Embase databases. In order to find the proper publications, the search has been conducted with the use of a combination of keywords like: “eslicarbazepine acetate", "focal-onset seizures treatment", "epilepsy treatment", "eslicarbazepine acetate pharmacokinetics”. The first step was to find proper publications from the last 10 years. The second step was to carry out an overview of the found publications.
Results of mentioned studies proved that for adults with medically uncontrolled partial-onset seizures, ESL monotherapy is well tolerated and effective over the long term, including the patients who transitioned from CBZ-CR monotherapy. Adjunctive ESL demonstrated a sustained therapeutic effect and was well-tolerated, safe, and efficacious during the treatment of adults with partial-onset seizures. Both 800 mg and 1200 mg once-daily doses were well tolerated. Moreover, significant improvements in depressive symptoms and quality of life domains were observed under long-term treatment with ESL.
Heo YA. Eslicarbazepine Acetate: A Review in Focal-Onset Seizures. CNS Drugs. 2020 Sep;34(9):989-1000. doi: 10.1007/s40263-020-00751-3. PMID: 32737793.
Shorvon SD, Trinka E, Steinhoff BJ, Holtkamp M, Villanueva V, Peltola J, Ben-Menachem E. Eslicarbazepine acetate: its effectiveness as adjunctive therapy in clinical trials and open studies. J Neurol. 2017 Mar;264(3):421-431. doi: 10.1007/s00415-016-8338-2. Epub 2017 Jan 18. PMID: 28101651; PMCID: PMC5336540.
Verrotti A, Loiacono G, Rossi A, Zaccara G. Eslicarbazepine acetate: an update on efficacy and safety in epilepsy. Epilepsy Res. 2014 Jan;108(1):1-10. doi: 10.1016/j.eplepsyres.2013.10.005. Epub 2013 Oct 23. PMID: 24225327.
Bialer M, Soares-da-Silva P. Pharmacokinetics and drug interactions of eslicarbazepine acetate. Epilepsia. 2012 Jun;53(6):935-46. doi: 10.1111/j.1528-1167.2012.03519.x. Epub 2012 May 21. PMID: 22612290.
Alcántara Montero A, Sánchez Carnerero CI. Eslicarbazepine acetate for neuropathic pain, headache, and cranial neuralgia: Evidence and experience. Neurologia (Engl Ed). 2019 Jul-Aug;34(6):386-395. English, Spanish. doi: 10.1016/j.nrl.2016.11.009. Epub 2017 Feb 16. PMID: 28215909.
Galiana GL, Gauthier AC, Mattson RH. Eslicarbazepine Acetate: A New Improvement on a Classic Drug Family for the Treatment of Partial-Onset Seizures. Drugs R D. 2017 Sep;17(3):329-339. doi: 10.1007/s40268-017-0197-5. PMID: 28741150; PMCID: PMC5629137.
Lattanzi S, Brigo F, Cagnetti C, Verrotti A, Zaccara G, Silvestrini M. Eslicarbazepine acetate in the treatment of adults with partial-onset epilepsy: an evidence-based review of efficacy, safety and place in therapy. Core Evid. 2018 Mar 8;13:21-31. doi: 10.2147/CE.S142858. PMID: 29563858; PMCID: PMC5846310.
Trinka E, Rocamora R, Chaves J, Moreira J, Ikedo F, Soares-da-Silva P; BIA-2093-311/EXT Investigators Study Group. Long-term efficacy and safety of eslicarbazepine acetate monotherapy for adults with newly diagnosed focal epilepsy: An open-label extension study. Epilepsia. 2020 Oct;61(10):2129-2141. doi: 10.1111/epi.16666. Epub 2020 Sep 17. PMID: 32944934; PMCID: PMC7693183.
Pazdera L, Sperling MR, Harvey JH, Sam MC, Strom LA, Blum D, Grinnell T, Cheng H. Efficacy and safety of eslicarbazepine acetate monotherapy in patients converting from carbamazepine. Epilepsia. 2018 Mar;59(3):704-714. doi: 10.1111/epi.14014. Epub 2018 Feb 16. PMID: 29450890.
Sperling MR, French J, Jacobson MP, Pazdera L, Gough M, Cheng H, Grinnell T, Blum D; Study 045 and 046 Investigators. Conversion to eslicarbazepine acetate monotherapy: A pooled analysis of 2 phase III studies. Neurology. 2016 Mar 22;86(12):1095-102. doi: 10.1212/WNL.0000000000002497. Epub 2016 Feb 24. PMID: 26911639; PMCID: PMC4826334.
Sperling MR, Abou-Khalil B, Harvey J, Rogin JB, Biraben A, Galimberti CA, Kowacs PA, Hong SB, Cheng H, Blum D, Nunes T, Soares-da-Silva P; 304 Study Team. Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: Results of a phase III, double-blind, randomized, placebo-controlled trial. Epilepsia. 2015 Feb;56(2):244-53. doi: 10.1111/epi.12894. Epub 2014 Dec 22. PMID: 25528898; PMCID: PMC4354260
Costa R, Steinhoff B, Gama H, Ikedo F, Rocha JF, Soares-da-Silva P. Safety, Tolerability and Efficacy of Eslicarbazepine Acetate as Adjunctive Therapy in Patients Aged ≥ 65 Years with Focal Seizures. Drugs Aging. 2018 Dec;35(12):1109-1117. doi: 10.1007/s40266-018-0602-y. PMID: 30387043; PMCID: PMC6267536.
Hufnagel A, Ben-Menachem E, Gabbai AA, Falcão A, Almeida L, Soares-da-Silva P. Long-term safety and efficacy of eslicarbazepine acetate as adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy: results of a 1-year open-label extension study. Epilepsy Res. 2013 Feb;103(2-3):262-9. doi: 10.1016/j.eplepsyres.2012.07.014. Epub 2012 Aug 4. PMID: 22871333.
Abraira L, Sanabria A, Ortega G, Quintana M, Santamarina E, Salas-Puig J, Toledo M. Cognicion social y funciones cognitivas en pacientes con epilepsia tratados con acetato de eslicarbacepina [Social cognition and cognitive functions in patients with epilepsy treated with eslicarbazepine acetate]. Rev Neurol. 2018 Jun 1;66(11):361-367. Spanish. PMID: 29790568.
Vaz-Da-Silva M, Nunes T, Almeida L, Gutierrez MJ, Litwin JS, Soares-Da-Silva P. Evaluation of Eslicarbazepine acetate on cardiac repolarization in a thorough QT/QTc study. J Clin Pharmacol. 2012 Feb;52(2):222-33. doi: 10.1177/0091270010391789. PMID: 21415284.
Mintzer S, Wechsler RT, Rogin JB, Gidal BE, Schwab M, Ben-Menachem E, Carreño M, da Silva PS, Moreira J, Li Y, Blum D, Grinnell T. Effects of adjunctive eslicarbazepine acetate on serum lipids in patients with partial-onset seizures: Impact of concomitant statins and enzyme-inducing antiepileptic drugs. Epilepsy Res. 2018 Mar;141:83-89. doi: 10.1016/j.eplepsyres.2018.02.001. Epub 2018 Feb 9. PMID: 29499473.
Falcão A, Pinto R, Nunes T, Soares-da-Silva P. Effect of repeated administration of eslicarbazepine acetate on the pharmacokinetics of simvastatin in healthy subjects. Epilepsy Res. 2013 Sep;106(1-2):244-9. doi: 10.1016/j.eplepsyres.2013.04.009. Epub 2013 May 30. PMID: 23726291.
Gidal BE, Mintzer S, Schwab M, Schutz R, Kharidia J, Blum D, Grinnell T, Sunkaraneni S. Evidence for a pharmacokinetic interaction between eslicarbazepine and rosuvastatin: Potential effects on xenobiotic transporters. Epilepsy Res. 2017 Sep;135:64-70. doi: 10.1016/j.eplepsyres.2017.05.005. Epub 2017 May 18. PMID: 28624574.
How to Cite
Copyright (c) 2022 Martyna Stefaniak, Zofia Pietrzak, Piotr Dzikowski, Emilia Nowicka, Michał Obel, Halina Piecewicz-Szczęsna
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Number of views and downloads: 341
Number of citations: 0